FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease
The U.S. Food and Drug Administration today issued a supplemental approval for Casgevy* (exagamglogene autotemcel) for patients aged 2 years and older with either sickle cell disease (SCD) with recurrent…